文献速递腹部技术与安全PETMR

18F-FDG PET-MRI联合T1 MOLLI定量图检测系统性硬化症肠道炎症与纤维化

18F-FDG PET-MRI with T1 MOLLI mapping to detect systemic sclerosis bowel inflammation and fibrosis.
PubMed 文献 · Eur J Radiol · 2018-06-26

前瞻性研究纳入16例系统性硬化症患者和15名健康对照,用3T PET-MRI及T1 MOLLI定量图评估肠道。患者大肠和小肠平均T1值均高于对照,87.5%患者肠道至少一段FDG-PET摄取达3级,患者大肠平均PET TBR高于对照,提示PET-MRI可无创同时评估肠道炎症和纤维化。

要点

  • 系统性硬化症患者大肠平均T1值1113±182 ms,高于对照的856±176 ms(p<0.001)。
  • 87.5%患者肠道至少一段FDG-PET摄取达3级,对照无一超过2级。
  • 患者大肠平均PET TBR为1.12±0.22,高于对照的0.82±0.20(p=0.02)。

核心结论

  • FDG-PET-MRI在系统性硬化症相关胃肠道受累中可无创同时评估肠道炎症和纤维化,结果令人鼓舞。

研究设计与样本

  • 前瞻性研究,纳入16例系统性硬化症患者和15名健康对照;所有患者和5名对照在Siemens 3T mMR上行PET-MRI(含T1-MOLLI定量图),10名对照仅行MRI;由两名培训有素的分析师联合手动分割大小肠,报告T1值和PET值,对照数据用于确定健康范围。

关键影像表现/征象

  • 患者大肠平均T1值1113±182 ms,高于对照的856±176 ms(p<0.001)。
  • 患者小肠平均T1值1331±239 ms,高于对照的1169±118 ms(p=0.02)。
  • 87.5%患者肠道至少一段FDG-PET摄取达3级,对照无一超过2级。
  • 患者大肠平均PET TBR为1.12±0.22,高于对照的0.82±0.20(p=0.02)。
  • 以对照PET-MR数据定义的PET和T1阈值判断,患者大肠中推测健康(非纤维化且非炎症)组织百分比为81.1±13.1%,低于对照的95.7±3.1%(p=0.03)。

诊断标准与关键数值

  • 以对照数据集确定健康范围,并据此定义PET和T1阈值。
  • FDG-PET节段摄取分级中,患者达3级及以上者占87.5%,对照最高为2级。
  • 大肠平均T1阈值对应患者1113±182 ms vs 对照856±176 ms(p<0.001)。
  • 小肠平均T1阈值对应患者1331±239 ms vs 对照1169±118 ms(p=0.02)。
  • 大肠PET TBR阈值对应患者1.12±0.22 vs 对照0.82±0.20(p=0.02)。

临床应用与阅片要点

  • 作者认为FDG-PET-MRI在系统性硬化症相关胃肠道受累中可无创同时评估肠道炎症和纤维化,结果令人鼓舞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Systemic sclerosis-associated gastrointestinal tract involvement (SSc-GIT) is an independent predictor of 2-year mortality in early SSc. Availability of non-invasive investigations will facilitate early diagnosis and monitoring.

HYPOTHESIS: We investigate the role of 18F-FDG-PET-MRI in SSc-GIT, hypothesizing that i) higher bowel FDG-PET uptake, a surrogate biomarker for inflammation, distinguishes healthy bowel from inflamed SSc-GIT; ii) MRI T1-MOLLI mapping, a surrogate biomarker for cardiac fibrosis, distinguishes healthy bowel from fibrotic SSc-GIT.

METHODS: In this prospective study, 16 SSc patients and 15 healthy controls were recruited. All SSc patients and 5 controls underwent PET-MRI (with T1-MOLLI mapping) on a Siemens 3T mMR; 10 controls underwent MRI without PET. Manual segmentation of the large and small bowels was performed jointly by two trained analysts in order to report T1 and PET values. Control dataset was used to assess normal healthy range. Mean T1 values, mean Tissue-to-Background (TBR) PET values, as well as amount of supposedly abnormal bowel (measured using the healthy ranges) was compared using Student's t-test and Cohen's d effect size.

RESULTS: Mean T1 values in large (1113 ± 182 ms vs 856 ± 176 ms; p-value < 0.001) and small bowel (1331 ± 239 ms vs 1169 ± 118 ms; p = 0.02) were higher in SSc patients than controls. 87.5% of the SSc patients' bowel had at least a grade 3 segmental FDG-PET uptake, while no controls showed more than a grade 2 segmental uptake. Patients had higher large bowel mean PET TBR (1.12 ± 0.22) than controls (0.82 ± 0.20, p = 0.02). Using PET and T1 thresholds defined using the control PET-MR data, the percentage of supposedly healthy (non-fibrotic and non-inflamed) tissue was significantly lower in SSc patients (81.1 ± 13.1%) than controls (95.7 ± 3.1%, p = 0.03) for the large bowel.

CONCLUSION: Our novel study of FDG-PET-MRI in SSc-GIT demonstrated promising results in non-invasively evaluating concurrently bowel inflammation and fibrosis.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Marchesseau S, Ng SA, Wang YT, et al. 18F-FDG PET-MRI with T1 MOLLI mapping to detect systemic sclerosis bowel inflammation and fibrosis. Eur J Radiol. 2018. PMID: 30017295. doi:10.1016/j.ejrad.2018.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。